Bausch Health Companies Inc. (TSX:BHC)

Canada flag Canada · Delayed Price · Currency is CAD
10.12
-0.26 (-2.50%)
Aug 25, 2025, 4:00 PM EDT
-2.50%
Market Cap3.83B
Revenue (ttm)13.44B
Net Income (ttm)133.66M
Shares Outn/a
EPS (ttm)0.36
PE Ratio28.67
Forward PE1.88
Dividendn/a
Ex-Dividend Daten/a
Volume310,509
Average Volume562,936
Open10.34
Previous Close10.38
Day's Range10.05 - 10.43
52-Week Range5.91 - 13.74
Beta0.41
RSI56.38
Earnings DateJul 30, 2025

About Bausch Health Companies

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]

Sector Healthcare
CEO Thomas Appio
Employees 20,700
Stock Exchange Toronto Stock Exchange
Ticker Symbol BHC
Full Company Profile

Financial Performance

In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.

Financial numbers in USD Financial Statements

News

Carl Icahn's Complete Divestment from Bausch Health Companies Inc

Carl Icahn's Complete Divestment from Bausch Health Companies Inc

3 days ago - GuruFocus

Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (Clindamycin Phosphate, Adapalene and Benzoyl Peroxide Gel), Now Available Through Public Drug Plans of Quebec and Saskatchewan

LAVAL, QC / ACCESS Newswire / August 21, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced that...

4 days ago - Accesswire

A Look Into Bausch Health Companies Inc's Price Over Earnings

In the current session, the stock is trading at $7.81, after a 0.26% increase. Over the past month, Bausch Health Companies Inc. (NYSE: BHC) stock increased by 14.81% , and in the past year, by 32.32...

5 days ago - Benzinga

Bausch + Lomb board members resign after Icahn agreement ends

Bausch + Lomb said on Monday Brett Icahn and Gary Hu have resigned from its board of directors after the termination of the agreement with billionaire Carl Icahn and some of his affiliates.

6 days ago - Reuters

Alembic Pharma shares jump over 2% as USFDA approves Tretinoin Cream USP

Shares of Alembic Pharmaceuticals gained over 2% on Monday, August 19, after the company announced that it has received final approval from the US Food and Drug Administration (USFDA) for its Abbrevia...

7 days ago - Business Upturn

Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes

LAVAL, QC / ACCESS Newswire / August 15, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) ("Bausch Health" or the "Company") today announced that Paulson Capital Inc. and certain affiliates and...

10 days ago - Accesswire

Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners

For the Sixth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a $10,000 Scholarship   LAVAL, QC / ACCESS Newswire / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BH...

18 days ago - Accesswire

Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript

Bausch Health Companies Inc. (NYSE:BHC) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Garen Sarafian - VP & Head of Investor Relations Jean-Jacques Charhon - Executiv...

25 days ago - Seeking Alpha

Bausch Health Announces Second Quarter 2025 Results

Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health Compani...

26 days ago - Accesswire

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Bausch Health Companies Inc. (NYSE: BHC) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ: DRRX), including a novel therapeutic molecule, larsucosterol . Larsucosterol, an endogenous sulf...

27 days ago - Benzinga

Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout

Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.

27 days ago - Benzinga

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

Phase 3 data show Bausch + Lomb’s LUMIFY Preservative Free eye drops are as safe and effective as the original LUMIFY in reducing ocular redness The multicenter study with 380 participants confirmed t...

27 days ago - Financial Post

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with al...

27 days ago - Accesswire

Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology ...

27 days ago - Business Wire

Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand

LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc., h...

4 weeks ago - Accesswire

Bausch Health Announces the Appointment of Two New Members to Its Board of Directors

LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and Sa...

4 weeks ago - Accesswire

CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs

This press release updates the headline of the previously posted release LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:B...

6 weeks ago - Accesswire

Bausch Health Appoints New Chief Accounting Officer

LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Steven Lee as Senior Vi...

6 weeks ago - Accesswire